Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide

Fig. 3

Decision curve for survival obtained using the multivariable Cox model. a The 1-year survival. b The 2-year survival. The dashed curve line is the net benefit of treating all patients; the black curve line is the net benefit of treating high-risk patients based on the prediction model; the black horizontal line is the net benefit of treating no patient

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us